Eli Lilly
Maker of 3 FDA-approved GLP-1 medications · Indianapolis, Indiana · founded 1876
By the GLP Index editorial team Updated How we source
Eli Lilly is the American drugmaker behind Mounjaro and Zepbound (tirzepatide), plus Trulicity and Foundayo, its new GLP-1 weight-loss pill.
GLP-1 medications Eli Lilly makes
Every Eli Lilly GLP-1 brand and the molecule inside it. Follow any link for our full guide on that medication.
- Zepbound 2023 tirzepatide · chronic weight management in adults Full guide
- Mounjaro 2022 tirzepatide · type 2 diabetes in adults Full guide
- Trulicity 2014 dulaglutide · type 2 diabetes in adults and children 10 and older Full guide
Active ingredients
What Eli Lilly is working on next
Investigational and newly approved GLP-1 assets beyond the current lineup.
- Foundayo (orforglipron) Approved 2026 The first oral small-molecule GLP-1 pill for weight loss, FDA-approved in April 2026 and taken any time of day without food or water restrictions.
- Retatrutide Phase 3 A triple GLP-1 / GIP / glucagon receptor agonist that produced the largest weight loss yet seen in obesity trials. Read our guide
Pipeline stages move quickly — dates reflect our last update (July 23, 2026) and can change with new trial data or FDA action.
Who is Eli Lilly?
Eli Lilly and Company is an American pharmaceutical company founded in 1876 by Colonel Eli Lilly and headquartered in Indianapolis, Indiana. Long known for insulin and neuroscience medicines, it became a central player in the GLP-1 era with tirzepatide — the dual-hormone molecule inside Mounjaro and Zepbound.
The company makes three FDA-approved GLP-1 medications — Mounjaro (tirzepatide for type 2 diabetes), Zepbound (tirzepatide for weight loss and obstructive sleep apnea), and the earlier Trulicity (dulaglutide). Mounjaro and Zepbound together now account for the majority of Lilly's revenue.
Lilly manufactures its medications at company-owned sites in the United States and abroad under FDA oversight, and has invested heavily in new plants to keep up with GLP-1 demand. Authentic Mounjaro and Zepbound pens come only from Eli Lilly — counterfeit and grey-market products are never sourced from the manufacturer.
How to get Eli Lilly's GLP-1 medications
These medications need a prescription. Telehealth providers we've reviewed can assess your eligibility online — here are a few, with our independent take.
FAQ
Common questions about Eli Lilly
Who makes Mounjaro?
Mounjaro is made by Eli Lilly and Company, the Indianapolis-based drugmaker that developed tirzepatide. Lilly also makes Zepbound, which uses the same active ingredient.
Is Eli Lilly the same company that makes Zepbound?
Yes. Eli Lilly makes both Mounjaro and Zepbound. Both contain tirzepatide — Mounjaro is approved for type 2 diabetes and Zepbound for weight loss and obstructive sleep apnea.
What weight-loss and diabetes drugs does Eli Lilly make?
Eli Lilly makes Mounjaro and Zepbound (both tirzepatide) and the older Trulicity (dulaglutide). It also makes Foundayo, a new oral GLP-1 weight-loss pill, and is developing retatrutide.
Where is Mounjaro manufactured?
Eli Lilly produces its GLP-1 medications at company-owned sites in the United States and abroad under FDA oversight. Authentic pens always come from Lilly, not third-party sellers.
Does Eli Lilly make a weight-loss pill?
Yes. Foundayo (orforglipron) is Lilly's oral GLP-1 pill for weight loss, FDA-approved in 2026 as the first small-molecule GLP-1 that can be taken any time of day without food or water restrictions.
Is Eli Lilly a reputable company?
Eli Lilly is one of the oldest and largest pharmaceutical companies in the world, publicly traded on the NYSE under LLY and founded in 1876. Its medications are FDA-approved and widely prescribed.
Sources
Every claim on this page traces to primary literature or FDA labeling. Browse the full evidence library.
- Eli Lilly and Company — official site (Eli Lilly and Company)
- Eli Lilly and Company — company information and drug list (Drugs.com)
- FDA approves Lilly's Foundayo (orforglipron) (Eli Lilly and Company)
Written by the GLP Index editorial team · Updated July 23, 2026 · How we source